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Background: Over 2.5 billion are at risk fromdengue fever (DF).
Early diagnosis of DF helps to diminish its burden on public health.
The real-time reverse transcription polymerase chain reaction (RT-
PCR) is the standard formolecular detectionof denguevirus (DENV)
in acute phase of DF. Real-time RT-PCR analysis is not suitable for
on-site of outbreak screening. The PCR devices are large, expensive,
and complex. In this study, a reverse transcription recombinase
polymerase ampliﬁcation (RT-RPA) assay was developed to detect
DENV 1-4.
Methods & Materials: RNA molecular standards comprised of
the 3′nontranslated region of DENV 1-4 were prepared. The assay
sensitivity was determined by analysis of eight assay runs of serial
dilutions of the RNA molecular standard. The assay speciﬁcity was
evaluated against a panel of viruses considered for differential diag-
nosis with DENV 1-4. The assay performance was validated by
testing 31blood samples in comparison to real-timeRT-PCR. To test
the possibility of using RT-RPA assays for outbreak investigations,
a mobile RT-RPA unit was operated in Kedougou, Senegal.
Results: The DENV 1-4 RT-RPA was rapid (3-10minutes). The
analytical sensitivity was 100 and 10 RNA molecules for DENV 1-3
and DENV 4, respectively. No cross reactivity with other viruses
causing similar clinical picture was observed. Both RT-RPA and
RT-PCR assays showed comparable results (96% sensitivity). The
RT-RPA assay was signiﬁcantly quicker than the real-time RT-PCR
assay (10minutes for RT-RPAand90minutes for real-timeRT-PCR).
In a ﬁeld study in Kedougou, Senegal, a magnetic-bead based total
nucleic acid extraction method was combined with RT-RPA on a
portable instrument (tubescanner). The RT-RPA assay was success-
fully used to detect DENV RNA extracted from gamma-irradiation
inactivated lyophilized virus supernatants. All operations were
carried out at an ambient temperature of 38 ◦C with auxiliary elec-
tricity tapped from a vehicle.
Conclusion: The developed DENV 1-4 RT-RPA assay constitutes
a suitable accurate, sensitive, and rapid assay for DF diagnosis dur-
ing the ﬁrst 5 days of infection. Moreover, the use of a portable
ﬂuorescence-reading device extends its application potential to
point-of-care use or at the outbreak site diagnosis.
http://dx.doi.org/10.1016/j.ijid.2014.03.453
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Background: Chikungunya virus (CHIKV) has re-emerged as a
dangerous mosquito-borne alphavirus and has been responsible
for several recent epidemics in tropical Africa and Asia. Despite the
recent resurgence of CHIKV, there are still no available vaccines or
therapeutics for the disease. Considering the current potential for
a global CHIKV pandemic, developing a CHIKV vaccine that elicits
potent and broadly neutralizing antibodies is of paramount impor-
tance.
Results: In our previous attempts to measure the immune
response against DNA-encoded antigens delivered by EP, we
observed that these immunogens are capable of providing pro-
tection from CHIKV viral infection in mice and inducing strong
neutralizing antibody responses in non-human primates. While
expressing CHIKV envelope in pseudoviral assays for these studies,
we observed that even in the absence of core protein, CHIKV enve-
lope would bud from transfected cells as long tubular structures
that mimic native envelope. We puriﬁed these virus-like-particles
(VLPs) from the cell culture supernatant and performed immuno-
genicity studies in Balb/C mice by intra-peritoneal administration.
Sera from immunized animals showed high reactivity with CHIKV-
envelope antigen in ELISA binding assays and high neutralization
activity.
Conclusion: Our results conﬁrm the in vivo effectiveness of syn-
thetic CHIKV VLPs as a useful vaccine platform. Furthermore, our
results suggest the possibility of extending this in vivo technology
to other pathogens for which a vaccine remains unavailable
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